AU2018438767B9 - Afucosylated antibodies and manufacture thereof - Google Patents

Afucosylated antibodies and manufacture thereof Download PDF

Info

Publication number
AU2018438767B9
AU2018438767B9 AU2018438767A AU2018438767A AU2018438767B9 AU 2018438767 B9 AU2018438767 B9 AU 2018438767B9 AU 2018438767 A AU2018438767 A AU 2018438767A AU 2018438767 A AU2018438767 A AU 2018438767A AU 2018438767 B9 AU2018438767 B9 AU 2018438767B9
Authority
AU
Australia
Prior art keywords
antibody
afucosylated
cells
cell
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018438767A
Other languages
English (en)
Other versions
AU2018438767A1 (en
AU2018438767B1 (enExample
AU2018438767B2 (en
Inventor
Hui-Jung Chen
Wen-Jiun Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biopharma Inc
Original Assignee
United Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biopharma Inc filed Critical United Biopharma Inc
Publication of AU2018438767A1 publication Critical patent/AU2018438767A1/en
Application granted granted Critical
Publication of AU2018438767B1 publication Critical patent/AU2018438767B1/en
Publication of AU2018438767B2 publication Critical patent/AU2018438767B2/en
Publication of AU2018438767B9 publication Critical patent/AU2018438767B9/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018438767A 2018-08-29 2018-08-29 Afucosylated antibodies and manufacture thereof Ceased AU2018438767B9 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/102995 WO2020042015A1 (en) 2018-08-29 2018-08-29 Afucosylated antibodies and manufacture thereof

Publications (4)

Publication Number Publication Date
AU2018438767A1 AU2018438767A1 (en) 2021-04-01
AU2018438767B1 AU2018438767B1 (enExample) 2023-07-13
AU2018438767B2 AU2018438767B2 (en) 2023-07-13
AU2018438767B9 true AU2018438767B9 (en) 2023-10-05

Family

ID=69642839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018438767A Ceased AU2018438767B9 (en) 2018-08-29 2018-08-29 Afucosylated antibodies and manufacture thereof

Country Status (11)

Country Link
US (1) US20210317499A1 (enExample)
EP (1) EP3818149A4 (enExample)
JP (1) JP7216806B2 (enExample)
KR (1) KR102596303B1 (enExample)
CN (1) CN113166728A (enExample)
AU (1) AU2018438767B9 (enExample)
BR (1) BR112021003765A2 (enExample)
CA (1) CA3110254C (enExample)
MY (1) MY197429A (enExample)
SG (1) SG11202101099PA (enExample)
WO (1) WO2020042015A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY198590A (en) * 2018-08-29 2023-09-07 United Biopharma Inc Afucosylated antibodies and manufacture thereof
JP7621481B2 (ja) * 2020-11-13 2025-01-24 アイバイオ， インク． Ｃｄ２５抗体
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113684322B (zh) * 2021-09-09 2024-01-23 上海药明生物技术有限公司 一种降低抗体类蛋白高聚甘露糖型水平的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106167525A (zh) * 2016-04-01 2016-11-30 北京康明生物药业有限公司 筛选超低岩藻糖细胞系的方法和应用
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
KR20050000380A (ko) * 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
KR20080032065A (ko) * 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
DK2808393T3 (en) * 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
US8469819B2 (en) * 2009-06-04 2013-06-25 Michael Parker McMain Game apparatus and game control method for controlling and representing magical ability and power of a player character in an action power control program
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Kirin Co., Ltd. Modified antibody composition
IL217216A0 (en) * 2011-12-27 2012-07-31 Merck Serono Sa Low fucose cell lins and uses thereof
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
US10077434B2 (en) * 2014-07-30 2018-09-18 Zumutor Biologics Inc. Non-fucosylated protein and methods thereof
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
CN106701823A (zh) * 2017-01-18 2017-05-24 上海交通大学 生产无岩藻糖单克隆抗体的cho细胞系建立及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106167525A (zh) * 2016-04-01 2016-11-30 北京康明生物药业有限公司 筛选超低岩藻糖细胞系的方法和应用
CN107881160A (zh) * 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMAI-NISHIYA ET AL: "Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells...", BMC BIOTECHNOLOGY, vol. 7, 30 Nov 2007, pg. 84 *
MALPHETTES ET AL: "Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies", BIOTECHNOLOGY AND BIOENGINEERING, 106(5), 8 April 2010, pages 774 - 783 *

Also Published As

Publication number Publication date
AU2018438767A1 (en) 2021-04-01
EP3818149A4 (en) 2022-03-23
US20210317499A1 (en) 2021-10-14
CA3110254A1 (en) 2020-03-05
WO2020042015A1 (en) 2020-03-05
AU2018438767B1 (enExample) 2023-07-13
KR102596303B1 (ko) 2023-10-30
CN113166728A (zh) 2021-07-23
KR20210047316A (ko) 2021-04-29
CA3110254C (en) 2023-08-29
EP3818149A1 (en) 2021-05-12
BR112021003765A2 (pt) 2021-05-25
JP7216806B2 (ja) 2023-02-01
JP2021534801A (ja) 2021-12-16
MY197429A (en) 2023-06-16
SG11202101099PA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
EP2595662B1 (en) Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile
KR101256257B1 (ko) 글리코실화된 항체
EP2596024B1 (en) Anti-cd19 antibody having adcc function with improved glycosylation profile
CN113645996A (zh) 抗claudin 18抗体及其使用方法
CA3110254C (en) Afucosylated antibodies and manufacture thereof
EP1900750A1 (en) Fully human high yield production system for improved antibodies
EP1911766A1 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
JP7292377B2 (ja) アフコシル化抗体およびその製造法
TWI745615B (zh) 去岩藻醣基化抗體及表現此抗體的細胞株
TWI748124B (zh) 去岩藻醣基化抗體的製造方法
HK40052496A (en) Afucosylated antibodies and manufacture thereof
HK40052495A (en) Afucosylated antibodies and manufacture thereof
HK1262617B (en) Obinutuzumab variants having altered cell death induction

Legal Events

Date Code Title Description
SREP Specification republished
SREP Specification republished
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired